Nova Patents
NO20002957L

Treatment with anti-ERBB2 antibodies

Abstract

The invention claims treatment and erbb2 excessive expression is characteristic of a disease the invention claims a method for. More specifically this invention claims using anti-erbb2 antibody and chemically curing agent combination of it is not the anthracene ring antibiotics the adriamycin the surface of soft ratio xing to treat and it is easy to be or diagnosis of the patient suffering from excessive expression of cancer patient erbb2.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

66 members in 18 offices

This recordMember, by publication datePriority claim8 more offices are in the list below

Priority claims8

Priority claims
DocumentOfficeKindDate
6934697United States of AmericaP
6934697United States of AmericaP
9826266United States of AmericaW
9826266United States of AmericaW
6934697–––
9826266–––
US19970069346P–––
WO1998US26266–––

Members66

Family members, oldest first
DocumentOfficeKind
CA2311409A1CanadaA1
CA2730373A1CanadaA1
WO9931140A1World Intellectual Property Organization (WIPO)A1
AU1908199AAustraliaA
ZA9811162BSouth AfricaB
NO20002957D0NorwayD0
NO20002957LThis recordNorwayL
NO20091147LNorwayL
EP1037926A1European Patent Office (EPO)A1
TR2000001689T2TürkiyeT2
TR200001689T2TürkiyeT2
CN1281468AChinaA
KR20010033019ARepublic of KoreaA
HK1030784A1Hong Kong, ChinaA1
IL136201A0IsraelA0
IL136201D0IsraelD0
BR9815363ABrazilA
JP2002508397AJapanA
AR020051A1ArgentinaA1
NZ504597ANew ZealandA
US2003147884A1United States of AmericaA1
US2003170234A1United States of AmericaA1
US2004037823A9United States of AmericaA9
US2005002928A1United States of AmericaA1
CN1269839CChinaC
CN1820734AChinaA
HK1091391A1Hong Kong, ChinaA1
US2007292419A1United States of AmericaA1
EP1947119A2European Patent Office (EPO)A2
US2008187533A1United States of AmericaA1
KR20080075042ARepublic of KoreaA
JP2010209081AJapanA
US7846441B1United States of AmericaB1
KR20100135337ARepublic of KoreaA
EP2275450A1European Patent Office (EPO)A1
EP2277919A1European Patent Office (EPO)A1
US7892549B2United States of AmericaB2
CA2311409CCanadaC
CN1820734BChinaB
IL136201AIsraelA
IL214084A0IsraelA0
IL214084D0IsraelD0
US2011250194A1United States of AmericaA1
US8075892B2United States of AmericaB2
US2012034213A1United States of AmericaA1
KR20120062942ARepublic of KoreaA
US8309087B2United States of AmericaB2
EP1947119A3European Patent Office (EPO)A3
JP2013056887AJapanA
KR20130036367ARepublic of KoreaA
US8425908B2United States of AmericaB2
US2013209459A1United States of AmericaA1
EP1037926B1European Patent Office (EPO)B1
US8642036B2United States of AmericaB2
DK1037926T3DenmarkT3
ES2450922T3SpainT3
US2014341886A1United States of AmericaA1
KR20150013870ARepublic of KoreaA
IL214084AIsraelA
JP2016006046AJapanA
JP2017039737AJapanA
IL234696AIsraelA
JP2017165737AJapanA
KR20180107323ARepublic of KoreaA
JP2019055979AJapanA
US2019240185A1United States of AmericaA1